PETALING JAYA: Genting Bhd
shares surged 10% to RM5.24 after its 20.3% subsidiary TauRx Pharmaceuticals Ltd revealed initial data from an Alzeimer’s drug clinical trials.
“TauRx’s lead investigative oral drug, hydromethylthionine mesylate, was tested on 598 people with Alzheimer’s.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
